美国 · 平台与数据 · Stocktwits
Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027
Separately, Merck reported positive Phase 3 Keynote-C93 results for its blockbuster Keytruda drug as a monotherapy in certain patients with advanced or recurrent endometrial…
在 Stocktwits 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (stocktwits.com)
